LEGION 100 Trademark

Serial Number: 99908104

LEGION 100 is a trademark filed by Syncromune, Inc. on June 26, 2026. The trademark is classified under Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Trademark Classes

10

Class 10 - Medical Apparatus

Surgical, medical, dental and veterinary apparatus and instruments

42

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

44

Class 44 - Medical Services

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Owner Contact Info

Syncromune, Inc. (14 trademarks)

2919 East Commercial Blvd.
Fort Lauderdale, FL 33308

Entity Type: 03

Legal Representation

Attorney of Record

Jessica L. Rothstein

3,890 trademarks filed View all →

Correspondence Address

Jessica L. Rothstein Goodwin Procter LLP

620 Eighth Avenue

New York, NY 10018

United States

Trademark Details

Filing Date

June 26, 2026

Registration Date

Not Registered

Goods & Services

Medical devices for the treatment of solid tumor cancers which cause partial intratumoral cell lysis and which deliver direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis; Medical apparatus, namely, devices which cause partial intratumoral cell lysis and which permit infusion and injection for locally targeted administration at the site of partial intratumoral lysis of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof

Providing a website featuring information in the field of health and medicine; conducting clinical trials of a system for the treatment of solid tumor cancers which causes partial intratumoral cell lysis and which delivers direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis

Providing a website featuring information in the field of clinical trials; conducting clinical trials of a system for the treatment of solid tumor cancers which causes partial intratumoral cell lysis and which delivers direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis